Get access to more insightful information

By signing up to Upstox today
signup
Shareholding Info
  • Promoters
    27.19 %
  • Foreign institutions-FII
    25.39 %
  • Other domestic institutions
    5.55 %
  • Retail and other
    36.29 %
  • Mutual Funds
    5.58 %

About Laurus Labs Limited


Laurus Labs is an Indian pharmaceutical and biotechnology company. It is headquartered in Hyderabad and was founded in 2005.

Initially founded as a CRAMS (contract research and manufacturing services) enterprise, the company swiftly diversified into antiretroviral drugs (ARVs). Within five years, it transitioned into a respected active pharmaceutical ingredients (API) focused company. Another half-decade later, Laurus Labs expanded into a fully integrated pharmaceutical company.

The market capitalisation of Laurus Labs Limited is over ₹22,600 crore as of January 10, 2024. Laurus Labs share price has gained over 18% in the last three years.


Business operations


Laurus Labs specialises in the development, production and distribution of pharmaceutical ingredients and their related intermediates worldwide. It also offers a range of services to the global pharmaceutical industry, including drug discovery, medicinal chemistry, lead optimisation, process development, scale-up, safety assessment, formulation development and analytical chemistry services for its clientele.

Laurus Labs operates through three primary business segments. Firstly, Laurus Generics focuses on the development, manufacturing, and sale of APIs and advanced intermediates, along with oral solid formulations and finished dosage forms (FDFs). Secondly, Laurus Synthesis specialises in key starting materials (KSM), intermediates and APIs, particularly for new chemical entities (NCEs). Laurus Bio concentrates on recombinant products, producing animal-origin-free products for safer and virus-free bio-manufacturing processes.

Laurus Limited collaborates with the top 10 global generic pharmaceutical companies, distributing its APIs across 56 countries. The company concentrates primarily on developing anti-retroviral, Hepatitis C and oncology drugs.

Laurus Limited is also deeply involved in the research and development (R&D) in high-growth potential areas. With a total of 322 filed patents, it currently owns 203. Over its operational tenure, Laurus Limited has successfully brought more than 60 products to market, spread across three distinct business segments: Generics API, generics finished dosage form (FDF) and synthesis.

The company has over 55 state-of-the-art R&D labs strategically positioned in India and the US. It manufactures a staggering 90-plus APIs across ten cutting-edge manufacturing facilities which have over 7 million litres of reactor capacity. The company has a workforce comprising over 5,000 professionals, among which 800-plus are dedicated research scientists. This team serves more than 200 customers spread across 56 countries.

Laurus Labs has API manufacturing facilities in Visakhapatnam, an FDF drug manufacturing facility situated in Achutapuram and a research and development centre at IKP Knowledge Park in Hyderabad. The Hyderabad centre is also approved by the Department of Scientific and Industrial Research, Ministry of Science and Technology of India (DSIR).

With its manufacturing and R&D, Laurus is among the global leaders in supplying anti-retroviral APIs and intermediates. Its cost-effective technologies contribute to improving access to affordable medication worldwide. Oncology is Laurus Limited's key strength. It offers an extensive range of APIs in this domain. Laurus consistently expands its portfolio and its focus extends to molecules in diabetes, ophthalmology and cardiovascular therapy areas.


Financial Highlights


  • Laurus Labs Limited's revenue from operations for FY23 stood at ₹6,040.55 crore, up by 22.4%, as compared to ₹4,935.57 crore in FY22.
  • The net profit after tax for FY23 was ₹793.43 crore compared to ₹832.23 crore during the previous year.
  • In FY23, the earnings before interest, tax, depreciation and amortisation (EBITDA) increased to ₹1,594 crore from the previous year's ₹1,436 crore.
  • The company's earnings per share (EPS) stood at ₹14.69 in FY23 compared to ₹15.42 in FY22.
Download Icon Download the Upstox App Today
close

Download Upstox Mobile App

upstox-qr-code